Findings

What do systematic reviews say?

9 questions · 9 findings · 3 reviews · Airways

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 11.1%GRADE not reported 1 · 11.1%Very low 0 · 0%Low 3 · 33.3%Moderate 4 · 44.4%High 0 · 0%

Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i vs placebo

Quality of life · people with pulmonary hypertension group 2 ‐ 4

The review found no eligible studies for this question.

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placebo

Quality of life · people with pulmonary hypertension due to CTEPH

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Low

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

Quality of life · people with pulmonary hypertension due to lung disease

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 238 participants
Moderate

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placebo

Quality of life · people with pulmonary hypertension due to left‐heart disease

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 52 participants
Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

Physical functioning component of health‐related quality of life, measured using various scales · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 267 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

Quality of life Kansas City Cardiomyopathy Quality‐of‐Life questionnaire (higher scores indicate better quality of life) · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

QoL · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 163 participants
GRADE not reported

Prostacyclin vs control

Quality of life · pulmonary arterial hypertension

1 finding from 1 review

Prostacyclin for pulmonary arterial hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 271 participants
Moderate

Intervention not reported

Health‐related Quality of Life: Dyspnoea domain of the CRQ · people with chronic obstructive pulmonary disease

1 finding from 1 review

Optimal intensity and type of leg exercise training for people with chronic obstructive pulmonary disease 2011 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 212 participants
Moderate